207 related articles for article (PubMed ID: 37422012)
1. The present and future of synthetic orexin receptor agonists.
Saitoh T; Sakurai T
Peptides; 2023 Sep; 167():171051. PubMed ID: 37422012
[TBL] [Abstract][Full Text] [Related]
2. TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy.
Ishikawa T; Hara H; Kawano A; Tohyama K; Kajita Y; Miyanohana Y; Koike T; Kimura H
J Pharmacol Exp Ther; 2023 Jun; 385(3):193-204. PubMed ID: 37001988
[TBL] [Abstract][Full Text] [Related]
3. OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy.
Yamamoto H; Nagumo Y; Ishikawa Y; Irukayama-Tomobe Y; Namekawa Y; Nemoto T; Tanaka H; Takahashi G; Tokuda A; Saitoh T; Nagase H; Funato H; Yanagisawa M
PLoS One; 2022; 17(7):e0271901. PubMed ID: 35867683
[TBL] [Abstract][Full Text] [Related]
4. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
5. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models.
Irukayama-Tomobe Y; Ogawa Y; Tominaga H; Ishikawa Y; Hosokawa N; Ambai S; Kawabe Y; Uchida S; Nakajima R; Saitoh T; Kanda T; Vogt K; Sakurai T; Nagase H; Yanagisawa M
Proc Natl Acad Sci U S A; 2017 May; 114(22):5731-5736. PubMed ID: 28507129
[TBL] [Abstract][Full Text] [Related]
6. Design and Synthesis of Orexin 1 Receptor-Selective Agonists.
Iio K; Hashimoto K; Nagumo Y; Amezawa M; Hasegawa T; Yamamoto N; Kutsumura N; Takeuchi K; Ishikawa Y; Yamamoto H; Tokuda A; Sato T; Uchida Y; Inoue A; Tanimura R; Yanagisawa M; Nagase H; Saitoh T
J Med Chem; 2023 Apr; 66(8):5453-5464. PubMed ID: 37043436
[TBL] [Abstract][Full Text] [Related]
7. Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model.
Ishikawa T; Hara H; Kawano A; Kimura H
Pharmacol Biochem Behav; 2022 Oct; 220():173464. PubMed ID: 36108771
[TBL] [Abstract][Full Text] [Related]
8. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
Yukitake H; Fujimoto T; Ishikawa T; Suzuki A; Shimizu Y; Rikimaru K; Ito M; Suzuki M; Kimura H
Pharmacol Biochem Behav; 2019 Dec; 187():172794. PubMed ID: 31654653
[TBL] [Abstract][Full Text] [Related]
9. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
Sun Y; Tisdale RK; Kilduff TS
Front Neurol Neurosci; 2021; 45():22-37. PubMed ID: 34052813
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists.
Nagahara T; Saitoh T; Kutsumura N; Irukayama-Tomobe Y; Ogawa Y; Kuroda D; Gouda H; Kumagai H; Fujii H; Yanagisawa M; Nagase H
J Med Chem; 2015 Oct; 58(20):7931-7. PubMed ID: 26267383
[TBL] [Abstract][Full Text] [Related]
11. The orexin receptor 2 (OX2R)-selective agonist TAK-994 increases wakefulness without affecting cerebrospinal fluid orexin levels in cynomolgus monkeys.
Yamada R; Narita N; Ishikawa T; Kakehi M; Kimura H
Pharmacol Biochem Behav; 2024 Jan; 234():173690. PubMed ID: 38061670
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists.
Zhang D; Perrey DA; Decker AM; Langston TL; Mavanji V; Harris DL; Kotz CM; Zhang Y
J Med Chem; 2021 Jun; 64(12):8806-8825. PubMed ID: 34101446
[TBL] [Abstract][Full Text] [Related]
13. [Development of a Therapeutic Drug for Narcolepsy].
Irukayama-Tomobe Y; Yanagisawa M
Brain Nerve; 2018 Nov; 70(11):1255-1263. PubMed ID: 30416119
[TBL] [Abstract][Full Text] [Related]
14. The orexin story, sleep and sleep disturbances.
Pizza F; Barateau L; Dauvilliers Y; Plazzi G
J Sleep Res; 2022 Aug; 31(4):e13665. PubMed ID: 35698789
[TBL] [Abstract][Full Text] [Related]
15. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes.
Willie JT; Chemelli RM; Sinton CM; Tokita S; Williams SC; Kisanuki YY; Marcus JN; Lee C; Elmquist JK; Kohlmeier KA; Leonard CS; Richardson JA; Hammer RE; Yanagisawa M
Neuron; 2003 Jun; 38(5):715-30. PubMed ID: 12797957
[TBL] [Abstract][Full Text] [Related]
16. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice.
Kaushik MK; Aritake K; Cherasse Y; Imanishi A; Kanbayashi T; Urade Y; Yanagisawa M
Sleep; 2021 Aug; 44(8):. PubMed ID: 33609365
[TBL] [Abstract][Full Text] [Related]
17. Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy.
Kaushik MK; Aritake K; Imanishi A; Kanbayashi T; Ichikawa T; Shimizu T; Urade Y; Yanagisawa M
Proc Natl Acad Sci U S A; 2018 Jun; 115(23):6046-6051. PubMed ID: 29784823
[TBL] [Abstract][Full Text] [Related]
18. Variants of the orexin2/hcrt2 receptor gene identified in patients with excessive daytime sleepiness and patients with Tourette's syndrome comorbidity.
Thompson MD; Comings DE; Abu-Ghazalah R; Jereseh Y; Lin L; Wade J; Sakurai T; Tokita S; Yoshida T; Tanaka H; Yanagisawa M; Burnham WM; Moldofsky H
Am J Med Genet B Neuropsychiatr Genet; 2004 Aug; 129B(1):69-75. PubMed ID: 15274044
[TBL] [Abstract][Full Text] [Related]
19. Orexin supplementation in narcolepsy treatment: A review.
Nepovimova E; Janockova J; Misik J; Kubik S; Stuchlik A; Vales K; Korabecny J; Mezeiova E; Dolezal R; Soukup O; Kobrlova T; Pham NL; Nguyen TD; Konecny J; Kuca K
Med Res Rev; 2019 May; 39(3):961-975. PubMed ID: 30426515
[TBL] [Abstract][Full Text] [Related]
20. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.
Nishino S; Kanbayashi T
Sleep Med Rev; 2005 Aug; 9(4):269-310. PubMed ID: 16006155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
